D Franchimont

Summary

Country: Belgium

Publications

  1. pmc Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis
    D Franchimont
    Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium
    Gut 53:987-92. 2004
  2. ncbi request reprint Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies
    D Franchimont
    Department of Gastroenterology, Erasme University Hospital, Free University of Brussels, 808, Lennik Road, 1070 Brussels, Belgium
    Ann N Y Acad Sci 1024:124-37. 2004
  3. pmc Profile of soluble cytokine receptors in Crohn's disease
    T Gustot
    Division of Gastroenterology, Erasme University Hospital, Free University of Brussels, 808 Lennik St, 1070 Brussels, Belgium
    Gut 54:488-95. 2005
  4. pmc An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease
    A Lemmers
    Department of Gastroenterology, Hepato Pancreatology and Digestive Oncology, Erasme Hospital, Universite Libre de Bruxelles ULB, Bruxelles, Belgium
    Clin Exp Immunol 156:518-27. 2009
  5. ncbi request reprint [Organized colorectal screening in French Community of Belgium and polyp surveillance]
    M Adler
    Département Médico chirurgical de Gastroentérologie, d Hépatopancréatologie et d Oncologie digestive, Hopital Erasme, Bruxelles
    Rev Med Brux 30:253-60. 2009
  6. ncbi request reprint [The medical gastroenterology department]
    J Deviere
    Rev Med Brux 23:57-62. 2002
  7. doi request reprint Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study
    R Marechal
    Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium
    Ann Oncol 23:1525-30. 2012
  8. ncbi request reprint Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
    N Franchimont
    Rheumatology Department, CHU Liege, Belgium
    Aliment Pharmacol Ther 20:607-14. 2004
  9. ncbi request reprint The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases
    P L De Jager
    Department of Neurology, Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Genes Immun 8:387-97. 2007
  10. pmc Review and clinical perspectives for the use of infliximab in ulcerative colitis
    R Panaccione
    University of Calgary, Calgary, Canada
    Can J Gastroenterol 22:261-72. 2008

Collaborators

Detail Information

Publications14

  1. pmc Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis
    D Franchimont
    Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium
    Gut 53:987-92. 2004
    ..We sought to determine whether this polymorphism was associated with Crohn's disease (CD) and/or ulcerative colitis (UC)...
  2. ncbi request reprint Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies
    D Franchimont
    Department of Gastroenterology, Erasme University Hospital, Free University of Brussels, 808, Lennik Road, 1070 Brussels, Belgium
    Ann N Y Acad Sci 1024:124-37. 2004
    ..Thus, the panoramic view of glucocorticoid actions on the immune system provides an interesting model for characterizing important biological pathways of immunosuppression...
  3. pmc Profile of soluble cytokine receptors in Crohn's disease
    T Gustot
    Division of Gastroenterology, Erasme University Hospital, Free University of Brussels, 808 Lennik St, 1070 Brussels, Belgium
    Gut 54:488-95. 2005
    ..Deficient sCR production could participate in the pathogenesis and course of Crohn's disease (CD). The aim of the study was to examine the profile of sCRs in CD patients and their modulation by infliximab and corticosteroids...
  4. pmc An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease
    A Lemmers
    Department of Gastroenterology, Hepato Pancreatology and Digestive Oncology, Erasme Hospital, Universite Libre de Bruxelles ULB, Bruxelles, Belgium
    Clin Exp Immunol 156:518-27. 2009
    ..This might explain the poor acute phase response induced by IL-6 in chronic liver disease...
  5. ncbi request reprint [Organized colorectal screening in French Community of Belgium and polyp surveillance]
    M Adler
    Département Médico chirurgical de Gastroentérologie, d Hépatopancréatologie et d Oncologie digestive, Hopital Erasme, Bruxelles
    Rev Med Brux 30:253-60. 2009
    ..Several strategies will be used to ensure follow up of this program and encourage wide participation of the population...
  6. ncbi request reprint [The medical gastroenterology department]
    J Deviere
    Rev Med Brux 23:57-62. 2002
    ....
  7. doi request reprint Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study
    R Marechal
    Department of Gastroenterology, Erasme University Hospital, Brussels, Belgium
    Ann Oncol 23:1525-30. 2012
    ..To evaluate in LARC patients, the feasibility and efficacy of a short intense course of induction oxaliplatin before preoperative chemoradiotherapy (CRT)...
  8. ncbi request reprint Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease
    N Franchimont
    Rheumatology Department, CHU Liege, Belgium
    Aliment Pharmacol Ther 20:607-14. 2004
    ..Crohn's disease is associated with low bone mineral density and altered bone metabolism...
  9. ncbi request reprint The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases
    P L De Jager
    Department of Neurology, Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Genes Immun 8:387-97. 2007
    ..16, 95% CI: 1.04-1.30; P=0.007) has a modest effect on risk of IBD. Our analysis, therefore, offers additional evidence that the TLR4 pathway - in this case, TLR4 and its signaling molecule TIRAP - plays a role in susceptibility to IBD...
  10. pmc Review and clinical perspectives for the use of infliximab in ulcerative colitis
    R Panaccione
    University of Calgary, Calgary, Canada
    Can J Gastroenterol 22:261-72. 2008
    ..Where there is a lack of evidence-based information, the expert panel provides its combined opinion derived from the members' clinical experiences...
  11. doi request reprint Predicting relapse in Crohn's disease: a biopsychosocial model
    A Bitton
    McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec, Canada, H3A 1A1
    Gut 57:1386-92. 2008
    ..Crohn's disease (CD) is a chronic relapsing inflammatory bowel disorder. Both biological and psychosocial factors may modulate the illness experience...
  12. ncbi request reprint [Crohn's disease]
    A Van Gossum
    Service Médico Chirurgical de Gastro entérologie, Hopital Erasme, U L B
    Rev Med Brux 23:35-42. 2002
    ..The use of these molecules requires an optimal adaptation of doses and a regular clinical and biological follow-up to prevent drug-related complications. Surgery should be reserved for treating complications...
  13. ncbi request reprint [Individual screening for colorectal cancer: which strategy for which patient?]
    A Demols
    Service de Gastro Entérologie Médicale, Hopital Erasme, U L B
    Rev Med Brux 22:A203-9. 2001
    ..Screening strategy should be decided on an individual basis considering the patient's benefit with respect to the informed consent...
  14. ncbi request reprint Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor
    D Franchimont
    Department of Gastroenterology CHU, University of Liege, Belgium
    J Clin Endocrinol Metab 84:2834-9. 1999
    ..This study suggests that the pattern of pro-/antiinflammatory cytokine secretion may alter the response of patients to glucocorticoid therapy...